Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGIZEKids
2025-524706-15-00Phase 3Authorised
- Sponsor
- Agios Pharmaceuticals
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in alpha thalassemia and beta thalassemia comparing Mitapivat with Placebo matching mitapivat (2 arms). Primary endpoint: Hemoglobin response. Planned start Aug 2026; status: authorised.
02
Drugs
mitapivat
03
Conditions
alpha thalassemiabeta thalassemia
Beyond the preview
Go deeper on 2025-524706-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524706-15-00.